Related Experiment Video
Updated: Jul 4, 2025

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF
Yan-Ni Zhao1,2,3, Zhou-di Liu2, Tao Yan2
1Joint Research Center on Medicine, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo, 315700, China.
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is a common metabolic disease that is substantially associated with obesity-induced chronic inflammation. Macrophage activation and macrophage-medicated inflammation play crucial roles in the development and progression of NAFLD. Furthermore, fibroblast growth factor receptor 1 (FGFR1) has been shown to be essentially involved in macrophage activation. This study investigated the role of FGFR1 in the NAFLD pathogenesis and indicated that a high-fat diet (HFD) increased p-FGFR1 levels in the mouse liver, which is associated with increased macrophage infiltration. In addition, macrophage-specific FGFR1 knockout or administration of FGFR1 inhibitor markedly protected the liver from HFD-induced lipid accumulation, fibrosis, and inflammatory responses. The mechanistic study showed that macrophage-specific FGFR1 knockout alleviated HFD-induced liver inflammation by suppressing the activation of MAPKs and TNF signaling pathways and reduced fat deposition in hepatocytes, thereby inhibiting the activation of hepatic stellate cells. In conclusion, the results of this research revealed that FGFR1 could protect the liver of HFD-fed mice by inhibiting MAPKs/TNF-mediated inflammatory responses in macrophages. Therefore, FGFR1 can be employed as a target to prevent the development and progression of NAFLD.
Insights
Fibroblast growth factor receptor 1 (FGFR1) inhibition protects against non-alcoholic fatty liver disease (NAFLD) by reducing liver inflammation and fat accumulation. Targeting FGFR1 in macrophages offers a promising therapeutic strategy for NAFLD.
Area of Science:
- Hepatology
- Immunology
- Metabolic Diseases
Background:
- Non-alcoholic fatty liver disease (NAFLD) is linked to obesity-driven inflammation.
- Macrophage activation and inflammation are key drivers in NAFLD progression.
- Fibroblast growth factor receptor 1 (FGFR1) is implicated in macrophage activation.
Purpose of the Study:
- To investigate the role of FGFR1 in the pathogenesis of NAFLD.
- To determine if targeting FGFR1 can mitigate NAFLD progression.
Main Methods:
- Utilized a high-fat diet (HFD) mouse model of NAFLD.
- Examined p-FGFR1 levels and macrophage infiltration in liver tissue.
- Performed macrophage-specific FGFR1 knockout and used FGFR1 inhibitors.
- Analyzed the effects on lipid accumulation, fibrosis, and inflammatory pathways (MAPKs, TNF).
Main Results:
- HFD increased liver p-FGFR1 levels and macrophage infiltration.
- Macrophage-specific FGFR1 knockout or inhibition protected against HFD-induced liver damage.
- FGFR1 inhibition suppressed MAPK/TNF signaling, reducing inflammation and fat deposition.
- This led to decreased hepatic stellate cell activation.
Conclusions:
- FGFR1 plays a critical role in mediating inflammatory responses in macrophages during NAFLD.
- Targeting FGFR1 in macrophages can protect the liver from HFD-induced injury.
- FGFR1 represents a potential therapeutic target for preventing and treating NAFLD.
More Related Videos
10:17An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
09:27Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
Published on: April 1, 2021